Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.

Current stem cell research & therapy Pub Date : 2024-01-01 DOI:10.2174/011574888X260032230925052240

Elham Zendedel, Lobat Tayebi, Mohammad Nikbakht, Elham Hasanzadeh, Shiva Asadpour

{"title":"Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.","authors":"Elham Zendedel, Lobat Tayebi, Mohammad Nikbakht, Elham Hasanzadeh, Shiva Asadpour","doi":"10.2174/011574888X260032230925052240","DOIUrl":null,"url":null,"abstract":"<p><p>Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":" ","pages":"1055-1071"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011574888X260032230925052240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间充质干细胞治疗新冠肺炎的临床试验19。

间充质干细胞（MSCs）由于其免疫调节、抗炎、组织修复和再生特性，正被研究作为一种新型病毒性疾病的治疗方法，但其确切过程尚不清楚。MSC治疗被发现通过改善肺部微环境，有效降低免疫系统过度激活，增加严重急性呼吸系统综合征冠状病毒2型感染后的内源性愈合。许多关于间充质干细胞的研究同时进行，我们可以通过收集和统计分析这些研究的数据来帮助加快这些研究的有效性。基于临床试验资料。gov和2020年11月16日，其中包括使用MSC治疗新冠肺炎患者领域的63项临床试验，根据该领域研究不断增加的趋势，并在荟萃分析研究的帮助下，有望有一天实现MSC的前景。本研究探讨了间充质干细胞在新冠肺炎治疗中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current stem cell research & therapy

自引率

0.00%

发文量